Valuation: Precision BioSciences, Inc.

Market Cap 239M 209M 193M 179M 339M 22.85B 345M 2.32B 903M 11.18B 896M 877M 38.82B P/E 2026 *
-3.35x
P/E 2027 * -3.59x
Enterprise Value 239M 209M 193M 179M 339M 22.85B 345M 2.32B 903M 11.18B 896M 877M 38.82B EV / Sales 2026 *
12.7x
EV / Sales 2027 * 19.1x
Free-Float
93.46%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision BioSciences, Inc.

1 day-1.62%
1 week+16.12%
Current month+16.41%
1 month+35.16%
3 months+52.75%
6 months+127.05%
Current year+119.95%
1 week 7.84
Extreme 7.845
9.62
1 month 6.03
Extreme 6.03
9.62
Current year 3.53
Extreme 3.53
9.62
1 year 3.53
Extreme 3.53
9.62
3 years 3.53
Extreme 3.53
21.9
5 years 3.53
Extreme 3.53
431.4
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 2021-10-14
Chief Tech/Sci/R&D Officer 53 2006-01-25
Director of Finance/CFO 59 2020-12-31
Director TitleAgeSince
Chairman 68 2020-10-31
Director/Board Member 65 2020-03-09
Director/Board Member 67 2021-04-11
Date Insider Type Main position Quantity % Market Cap.
06-02Free

Director

20,979 0.0872%
06-02Free

Director

20,979 0.0872%
06-02Free

Director

20,979 0.0872%
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%+16.12%+102.43%-52.34% 239M
-0.24%+1.85%+3.13%+8.40% 49.74B
-0.97%+0.93%+419.35%+595.52% 40.49B
-2.88%+3.34%+22.90%+56.05% 34.35B
-2.80%-0.18%+23.32%-7.57% 34.75B
-0.79%+2.02%+3.83%+36.42% 26.98B
+2.29%+2.46% - - 16.58B
-3.17%-3.31%+62.98%+117.38% 15.6B
-2.44%+6.42%+103.86%+101.71% 14.27B
-2.70%-2.04%+12.37%+17.77% 13.76B
Average -1.66%+5.36%+83.80%+97.04% 24.68B
Weighted average by Cap. -1.68%+4.38%+93.38%+133.33%

Financials

2026 *2027 *
Net sales 18.81M 16.5M 15.23M 14.07M 26.68M 1.8B 27.21M 183M 71.15M 881M 70.64M 69.09M 3.06B 12.52M 10.98M 10.14M 9.37M 17.76M 1.2B 18.11M 122M 47.36M 587M 47.02M 45.99M 2.04B
Net income -77.69M -68.14M -62.91M -58.13M -110M -7.44B -112M -756M -294M -3.64B -292M -285M -12.64B -86.26M -75.66M -69.85M -64.55M -122M -8.26B -125M -840M -326M -4.04B -324M -317M -14.03B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
66
Date Price Change Volume
26-07-08 US$9.150 -1.08% 345,364
26-07-07 US$9.250 +12.26% 1,249,634
26-07-06 US$8.240 +0.73% 424,624
26-07-02 US$8.180 +3.81% 600,930
26-07-01 US$7.880 +0.25% 446,050
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.250USD
Average target price
29.60USD
Spread / Average Target
+220.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock